RLYB (Rallybio Corp) יחס שווי שוק לשווי בספרים

This chart shows the market valuation of Rallybio Corporation (RLYB) fixed at 0.90. The company's current status is characterized by a lack of revenue due to ongoing clinical trials, which temporarily limits its pricing power. Operational activities rely on strict temperature control during the transportation of orphan drugs. The fundamental potential is based on the development of a unique method to protect the fetus from maternal immunity in FNAIT.

The market-to-book ratio measures the premium of a company's market value over its net assets. For Rallybio Corporation (RLYB), this ratio reflects investor expectations regarding the success of R&D projects in preventive medicine for pregnant women. The current value of 0.90 in the market-to-book capitalization trend indicates the degree of overvaluation of intellectual capital. An upward curve signals market confidence in breakthrough antibodies, while an excessive divergence of the market price from assets creates correction risks.